pamidronatdinatrium pfizer 6 mg/ml koncentrat till infusionsvätska, lösning
pfizer ab - pamidronatdinatrium, vattenfri - koncentrat till infusionsvätska, lösning - 6 mg/ml - mannitol hjälpämne; pamidronatdinatrium, vattenfri 6 mg aktiv substans - pamidronat
pamidronatdinatrium pfizer 9 mg/ml koncentrat till infusionsvätska, lösning
pfizer ab - pamidronatdinatrium, vattenfri - koncentrat till infusionsvätska, lösning - 9 mg/ml - mannitol hjälpämne; pamidronatdinatrium, vattenfri 9 mg aktiv substans - pamidronat
natriumjodid (i-123) map 26 mbq/ml injektionsvätska, lösning
map medical technologies oy - natriumjodid(i-123) - injektionsvätska, lösning - 26 mbq/ml - natriumjodid(i-123) 26 mbq aktiv substans - natriumjodid(i-123)
natriumjodid (i-131) cis 1110 mbq/ml oral lösning
cis bio international - natriumjodid(i-131) - oral lösning - 1110 mbq/ml - natriumjodid(i-131) 1110 mbq aktiv substans - natriumjodid(i-131)
natriumjodid (i-131) amersham health 200-4000 mbq/ml injektionsvätska, lösning
amersham health as - natriumjodid(i-131) - injektionsvätska, lösning - 200-4000 mbq/ml - natriumjodid(i-131) 200 - 4000 mbq aktiv substans - natriumjodid(i-131)
natriumjodid (i-131) amersham health 37-3700 kbq kapsel, hård
ge healthcare as - natriumjodid(i-131) - kapsel, hård - 37-3700 kbq - natriumjodid(i-131) 37 - 3700 kbq aktiv substans - natriumjodid(i-131)
natriumjodid (i-131) amersham health 4 - 7 gbq/ml oral vätska
ge healthcare as - natriumjodid(i-131) - oral vätska - 4 - 7 gbq/ml - natriumjodid(i-131) 4000 - 7000 mbq aktiv substans - natriumjodid(i-131)
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklid imaging - terapeutiska radioaktiva läkemedel - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
natriumjodid (i-125) amersham health 600-1000 mbq/ml injektionsvätska, lösning
amersham health as - natriumjodid(i-125) - injektionsvätska, lösning - 600-1000 mbq/ml - natriumjodid(i-125) 600 - 1000 mbq aktiv substans - radiofarmaka jod-125 natriumjodid
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.